Daratumumab, lenalidomide, and dexamethasone combination in relapsed/refractory myeloma patients: a real-life single-center experience.

In recent years, the clinical outcome of multiple myeloma (MM) patients has improved due to the introduction of several new agents and of immunotherapy. The combination of novel drugs has allowed i...